Last $4.90 USD
Change Today 0.00 / 0.00%
Volume 1.5K
CLTX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

celsus therapeutics-spon adr (CLTX) Snapshot

Open
$4.90
Previous Close
$4.90
Day High
$5.39
Day Low
$4.90
52 Week High
01/15/14 - $11.90
52 Week Low
04/15/14 - $4.63
Market Cap
27.2M
Average Volume 10 Days
32.8K
EPS TTM
$-1.70
Shares Outstanding
5.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELSUS THERAPEUTICS-SPON ADR (CLTX)

Related News

No related news articles were found.

celsus therapeutics-spon adr (CLTX) Related Businessweek News

No Related Businessweek News Found

celsus therapeutics-spon adr (CLTX) Details

Celsus Therapeutics Plc, a development stage company, is engaged in the discovery and development of non-steroidal and synthetic anti-inflammatory drugs. The company’s principal product candidate is MRX-6, a topical cream that is in Phase 2 clinical trials for the treatment of atopic dermatitis. Its product candidates in pre-clinical studies comprise OPT-1 for the treatment of conjunctivitis, post-operative inflammation, and/or dry eye; and CFX-1 to treat cystic fibrosis and other inflammatory diseases. The company was formerly known as Morria Biopharmaceuticals Plc and changed its name to Celsus Therapeutics Plc in June 2013. Celsus Therapeutics Plc is headquartered in London, the United Kingdom.

5 Employees
Last Reported Date: 11/20/14

celsus therapeutics-spon adr (CLTX) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $403.0K
Chief Financial Officer
Total Annual Compensation: $213.5K
Chief Medical Officer
Total Annual Compensation: $40.0K
Compensation as of Fiscal Year 2013.

celsus therapeutics-spon adr (CLTX) Key Developments

Celsus Therapeutics plc Announces Management Changes

Celsus Therapeutics Plc announced Executive Chairman Mark Cohen stepped down as a member of nominating and governance committee. The board of directors appointed Robert Doman as his replacement on the nominating and governance committee effective January 1, 2015.

Celsus Therapeutics Plc Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-10-2014 04:30 PM

Celsus Therapeutics Plc Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-10-2014 04:30 PM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: Gur A. Roshwalb, Chief Executive Officer, Director and Member of Research & Development Committee.

Celsus Therapeutics Seeks Acquisitions

Celsus Therapeutics Plc (NasdaqCM:CLTX) has filed a shelf registration in the amount of $75.00 million. Celsus Therapeutics intends to use a portion of the proceeds to pay off outstanding indebtedness, if any, and/or acquire or invest in complementary businesses, products and technologies.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLTX:US $4.90 USD 0.00

CLTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLTX.
View Industry Companies
 

Industry Analysis

CLTX

Industry Average

Valuation CLTX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.4x
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELSUS THERAPEUTICS-SPON ADR, please visit www.celsustx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.